肝动脉介入栓塞术治疗肝血管瘤患者疗效及血清GPDA、GP73和β2-MG水平变化*

doi:10.3969/j.issn.1672-5069.2020.06.037

Abstract

Abstract: Objective The aim of this study was to investigate the efficacy of transhepatic artery embolization (TAE) in treatment of patients with hepatic hemangioma and serum glycylproline dipeptide aminopeptidase (GPDA), Golgi protein 73 (GP73) and β2-microglobulin (β2-MG) level changes. Methods 60 patients with hepatic hemangioma were treated in our hospital between January 2017 and January 2019, and 30 received TAE and another 30 underwent open hepatectomy. After operation, all patients were followed-up for six months. Serum GPDA, GP73, β2-MG, tumor necrosis factor-α (TNF-α), tumor-specific growth factor (TSGF) and alpha-fetoprotein (AFP) were assayed by ELISA. Results The operation time and postoperative hospital stay in TAE-treated patients were (84.7±21.9) min and (6.7±1.3) d, significantly shorter than [(126.8±60.5) min and (9.6±5.8) d, P<0.05], and bleeding during operation was (110.7 ± 13.5) mL, much less than [(315.5±17.8) mL, P<0.05] in those receiving open hepatectomy; 1 week after surgery, serum GPDA, GP73,β2-MG, TNF-α, TSGF and AFP levels in the interventional group were (62.6±9.8)U/L, (64.3±6.7)μg/L, (1.4±0.5)mg/L, (1.3±0.5)mg/L, (35.5±4.3)U/mL and (2.5±0.6)mg/L, all significantly lower than 【(86.4±11.5)U/L, (112.2±9.3)μg/L, (2.3±0.9)mg/L, (2.1±1.2)mg/L, (61.3±9.8)U/mL and (4.7±0.8)mg/L, respectively, P<0.05】 in patients receiving open hepatectomy; the incidence of complications after operation in the interventional group was 13.3%, which was obviously lower than that in the open hepatectomy group (30.0%, P<0.05); the total effective rate in the interventional group at six-month follow-up was 93.3%, which was obviously higher than that in the open hepatectomy group (80.0%, P<0.05). Conclusion The transhepatic artery embolization in the treatment of patients with hepatic hemangioma is efficacious, which might reduce serum GPDA, GP73 and β2-MG levels, and lead to less post-operational complications.

Key words: Hepatic hemangioma, Transhepatic artery embolization, Glycylproline dipeptide aminopeptidase, Golgi protein 73, β2-microglobulin, Therapy

Wang Chen, Zhang Xuebin, Cheng Le. Efficacy of transhepatic artery embolization in treatment of patients with hepatic hemangioma[J]. Journal of Practical Hepatology, 2020, 23(6): 905-908.

References

[1] 金震, 周晓春, 马红霞. 椎旁阻滞联合全身麻醉对肝血管瘤切除术患者疼痛及术后恢复的影响. 实用肝脏病杂志, 2019, 22(6): 908-911.
[2] Venkatram K, Sunil K B, Abhilash S, et al. Atypical exophytic liver mass: giant pedunculated hepatic haemangioma masquerading as a gastrointestinal stromal tumour of the gastric wall. SA J Radiol, 2019, 23(1): 1697-1698.
[3] Nassim F, Schlemmer H P, Friedhelm R, et al. CT and ultrasound-characteristics of hepatic lesions in patients with multiple endocrine neoplasia syndrome: a retrospective image review of 25 cases. PLoS One,2019, 14(2): 212-2186.
[4] Ju H L, Chang J Y, Young H K,et al. Living-donor liver transplantation for giant hepatic hemangioma with diffuse hemangiomatosis in an adult: a case report. Clin Mol Hepatol, 2018, 24(2): 163-168.
[5] Guodong P, Zuyun D, Chunchun S, et al. Heterogeneity analysis of triphasic CT scan perfusion parameters in differential diagnosis of hepatocellular carcinoma and hemangioma. Medicine, 2018, 97(38): 12512-12513.
[6] 夏锋, 李雪松. 肝血管瘤诊断和治疗多学科专家共识(2019版). 中国实用外科杂志, 2019, 39(8): 761-765.
[7] Maria G, Gerald B, Alison K, et al. History of the infantile hepatic hemangioma: from imaging to generating a differential diagnosis. World J Clin Pediatr,2016,5(3): 273-280.
[8] Zidan A, Ibrahim H, Farrag M, et al. Giant haemangioma of the liver with haemangiodudenal fistula: the first reported case in literature. Ann R Coll Surg Engl,2015, 97(6): 90-92.
[9] Igarashi G, Kenichiro M, Naoya S, et al. Interventional treatment for hepatic hemangioma accompanied by arterio-portal shunt with ascites. Intern Med, 2018, 57(19): 2847-2851.
[10] 闫军, 李亮. 腹腔镜肝血管瘤切除术患者术后感染相关因素分析. 实用肝脏病杂志, 2017, 20(3): 341-344.
[11] 殷杰, 徐新宝, 朱日祥. 腹腔镜肝切除术治疗肝血管瘤58例临床分析. 中华肝脏外科手术学电子杂志, 2018, 7(6): 469-472.
[12] Hiroyuki S, Yuki S, Shozo M, et al. Hepatic sclerosing hemangioma with predominance of the sclerosed area mimicking a biliary cystadenocarcinoma. Case Reports Hepatol, 2018, 20(1): 7353-7357.
[13] Umberto G R, Nicola C, Francesco P, et al. Spontaneous hepatic haemangioma rupture and hemoperitoneum: a double problem with a single stage interventional radiology solution. Clin Exp Emerg Med, 2019, 6(2): 169-172.
[14] Jingjun W, Ailian, Jingjing C, et al. Radiomics-based classification of hepatocellular carcinoma and hepatic haemangioma on precontrast magnetic resonance images. BMC Med Imaging,2019, 19(1): 23-24.
[15] Xin L, Chao A, Fangyi L, et al. The value of 3D visualization operative planning system in ultrasound-guided percutaneous microwave ablation for large hepatic hemangiomas: a clinical comparative study. BMC Cancer, 2019, 19(7): 550-551.
[16] Ryota K, Nozomi Mi, Yoshiaki M, et al. A hepatic sclerosing hemangioma emerged in the postoperative course of multiple gastric carcinoid tumors masquerading as metachronous liver metastasis. Int J Surg Case Rep,2019, 58(1): 1-5.
[17] Xiao F W, Bai X M, Wei Y, et al. Differentiation of atypical hepatic hemangioma from liver metastases: Diagnostic performance of a novel type of color contrast enhanced ultrasound. World J Gastroenterol, 2020,26(9): 960-972.
[18] Shaohong W, Jun G, Mengmeng Y, et al. Intratumoral coagulation by radiofrequency ablation facilitated the laparoscopic resection of giant hepatic hemangioma: a surgical technique report of two cases. Oncotarget, 2017, 8(31): 52006-52011.
[19] Li W, Li A, Wang B, et al. Automatic spectral imaging protocol and iterative reconstruction for radiation dose reduction in typical hepatic hemangioma computed tomography with reduced iodine load: a preliminary study. Br J Radiol, 2018, 91(1087): 978-981.
[20] Hara K, Fukumura Y, Saito T, et al. A giant cord hemangioma with extramedullary hematopoiesis and elevated maternal serum human chorionic gonadotropin: a case report and review of the literature. Diagn Pathol, 2015, 10(1): 154-155.
[21] Josephina A V, Manon B, Eleni L, et al. Receiver operating characteristic analysis of diffusion-weighted magnetic resonance imaging in differentiating hepatic hemangioma from other hypervascular liver lesions. J Comput Assist Tomogr, 2018, 32(5): 750-756.
[22] Masaki W, Shigeyuki U, Mitsuyoshi T, et al. Multiple hepatic sclerosing hemangioma mimicking metastatic liver tumor successfully treated by laparoscopic surgery: report of a case. Int J Surg Case Rep, 2015,8(1): 137-140.
[23] 张志成, 袁广庆, 莫灿均. 肝动脉栓塞术治疗三种类型肝血管瘤患者疗效及安全性分析. 实用肝脏病杂志, 2019, 22(5): 736-739.

Efficacy of transhepatic artery embolization in treatment of patients with hepatic hemangioma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhou Xinmin, Ding Xiaopeng. Highlights of conventional supporting therapy for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(1): 4-6.
[2]	Liu Qi, Hao Jiqing. Immunotherapy of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(1): 7-9.
[3]	Zheng Zhiheng, Li Weiyun, Hui Zhenyu,et al. Serological and virological response topegylated interferon α-2a and entecavir combination in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 19-22.
[4]	Lin Jinxiang, Yang Keli. Comparison of response toPEG-IFNα-2a or PEG-IFNα-2b in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(1): 27-30.
[5]	Fan Bingdong, Zhang Guohua, Wang Jun. An observation of clinical efficacy of sofosbuvir/vipatavir and ribavirin combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 31-34.
[6]	Yang Xiaodong,Jia Ting,Zhang Xiuling, et al. Short-term efficacy of danorevir and peginterferon-α in the treatment of patients with genotype 3 infected chronic hepatitis C [J]. Journal of Practical Hepatology, 2021, 24(1): 35-38.
[7]	Wei Xiuqin, Yan Xiaoxia, Shi Guorong, et al. Short-termefficacy of atorvastatin and tiopronin combination in the treatment of patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(1): 47-50.
[8]	Li Zhao, Huang Zansong , Li Fan. Application of fenofibrate and bicyclol combination in treatment of patients with non-alcoholic fatty liver diseases and changes of hepatic PPARγ₂ [J]. Journal of Practical Hepatology, 2021, 24(1): 59-62.
[9]	Chen Jinyu, Guo Xiaoxia, Zhong Xiaoni. Efficacy of bifidobacterium triple viable capsuleand metformin in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 63-66.
[10]	Chen Yanping, Huang Shaoqiang,Deng Xin ,et al. Short-term efficacy of tiopronin and polyene phosphatidylcholine combination in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 67-70.
[11]	Cai Yu, Wang Mengchun, Qiu Xinping, et al. Improvement of liver function and subsiding jaundice by compound glycyrrhizin and adenosylmethionine succinate in the treatment of patients with alcoholic hepatitis [J]. Journal of Practical Hepatology, 2021, 24(1): 71-74.
[12]	Wu Chang,Tian Yuan,Liu Hongyan. Short-term efficacy of live clostridium butyricum in assisting tiopronin and metadoxine in treatment of patients with alcoholic liver disease [J]. Journal of Practical Hepatology, 2021, 24(1): 75-78.
[13]	Li Qingling, He Shuguang, Yi Xiaoming, et al. Changes of peripheral blood lymphocyte PD-1 and PD-L1 expression in patients with autoimmune hepatitis receiving tripterygium wilfordii polyglycosides and magnesium iso-glycyrrhizate [J]. Journal of Practical Hepatology, 2021, 24(1): 79-82.
[14]	Zeng Jiao, Guo Guihai. Efficacy and safety of polyethylene glycol and lactulose in the treatment of patients with hepatic encephalopathy:a Meta-analysis [J]. Journal of Practical Hepatology, 2021, 24(1): 99-102.
[15]	Fan Jing, Xu Jing, Yuan Xue. Combination of rifaximin and lactulose improves clinical efficacy and mortality in hepatitis B cirrhotic patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(1): 103-106.